Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNYNYSE / NASDAQHealthcareLarge cap

$143.82-$4.00 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$40.5B
P/E
129.2x
EV / EBITDA
61.6x
Revenue
$3.7B
Net margin
8.4%
ROCE
32.0%

-67.7% over the last year

Alnylam Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-37.7%
3M
-37.3%
6M
-51.8%
1Y
-67.7%
5Y
-20.5%

52-week range

Day change -$4.00 (-2.7%) from $148 to $144 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ALNY, bought on each weekday since 2021.

News & filings

What Alnylam Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on capital employed of 32.0%.

Concerns (1)

  • EV / EBITDA of 61.6 against a peer median of 16.7.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Read moreShow less

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
132.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$40.5B
P/E
129.2x
P/B
51.4x
EV / EBITDA
61.6x
EV / Sales
10.5x
P/S
10.9x
52-week high
$473.29
52-week low
$143.82

Profitability

Operating margin
13.5%
Net margin
8.4%
EBITDA margin
17.0%
ROE
39.8%
ROCE
32.0%
ROA
6.3%
Asset turnover
0.75

Growth

Revenue
$3.7B
Revenue growth, 1Y
65.2%
Revenue CAGR, 3Y
53.0%
Net profit growth, 1Y
-212.8%
Free cash flow
$465.4M

Solvency

Current ratio
2.76
Debt / Equity
1.62
Debt / Assets
0.26
CFO / Net profit
1.67
Cash / Market cap
7.2%

Where the revenue went

Of every $100 of FY2025 revenue, $8 was left as net income.

Alnylam Pharmaceuticals, Inc. income statement flow, FY2025
Alnylam Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$681.9M
RevenueGross profit$3.0B
Gross profitResearch and development$1.3B
Gross profitSelling, general and administrative$1.2B
Gross profitOther operating expenses$0.00
Gross profitOperating income$501.6M
Operating incomePretax income$323.1M
Operating incomeInterest and other expense$178.4M
Pretax incomeTax and other$9.4M
Pretax incomeNet income$313.8M

Revenue and net profit

Revenue grew 65.2% in FY2025; net profit is the dashed line.

Alnylam Pharmaceuticals, Inc. revenue and net profit by fiscal year
Alnylam Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.0B-$1.1B
FY2023$1.8B-$440.2M
FY2024$2.2B-$278.2M
FY2025$3.7B$313.7M

Cash flows

FY2025: $524.1M from operations, $465.4M free after investment (dashed).

Alnylam Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Alnylam Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$541.3M-$613.3M
FY2023$104.2M$41.9M
FY2024-$8.3M-$42.6M
FY2025$524.1M$465.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$3.7B+65.2%1Y
EBITDA
$631.4M
Net profit
$313.7M
Cash from operations
$524.1M
Free cash flow
$465.4M
Revenue CAGR, 3Y
53.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$3.7B$631.4M$313.7M$465.4M39.8%+65.2%-212.8%

Monthly returns

Month-by-month returns of ALNY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$5.0B
Liabilities$4.2B
Equity$789.2M
Paid-in capital$7.5B
Retained earnings-$6.7B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ALNY highlighted.

P/E against peers

ALNY trades at 129.2x earnings against a peer median of 30.1x (a 329% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Alnylam Pharmaceuticals, Inc.ALNYthis companyP/E ↑ premium$40.5B129.2x51.4x39.8%61.6x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Humana Inc.HUM$42.0B35.4x2.4x6.7%—
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Peer median—30.1x5.3x20.1%16.7x

Year-to-date ROI

ALNY since 1 January, against earlier years.

Historical volatility

ALNY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Alnylam Pharmaceuticals, Inc. operating margin by fiscal year
Alnylam Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-75.7%
FY2023-15.4%
FY2024-7.9%
FY202513.5%
LineFY2025
Cost of revenueCost Of Revenue$681.9M
Gross profitGross Profit$3.0B
Operating expensesOperating Expense$2.5B
Research and developmentResearch And Development$1.3B
Rent expense supplementalRent Expense Supplemental$193.4M
Total expensesTotal Expenses$3.2B
Pretax incomePretax Income$323.1M

Learn while you research

Academy chapters picked for Alnylam Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 129.2, learn when high multiples are justified.6 min read
  3. 03 Growth Investing65% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Leverage RatiosDebt/Equity of 1.62 is elevated, understand what that means for solvency.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →